[1PS-109]
Development of PEGylated Albumin-Based Nanoparticles for Cancer Therapy and Theranostic Applications
발표자박효진 (성균관대학교)
연구책임자정지훈 (성균관대학교)
Abstract
Paclitaxel (PTX) is a potent chemotherapeutic commonly employed in managing recurrent and metastatic breast cancer. Nevertheless, its low water solubility requires formulation with oil- or surfactant-based vehicles, which can induce hypersensitivity reactions and hinder effective drug delivery to tumor tissues. To address these limitations, the present study introduces a solvent-free method to formulate PTX-loaded nanoparticles using PEG-conjugated human serum albumin (HSA-PEG). The nanoparticles were fabricated through a simple film-casting followed by hydration, yielding stable PTX-loaded particles. These nanoparticles showed efficient intracellular delivery and potent cytotoxic effects across several breast cancer cell lines. In a breast cancer xenograft mouse model, intravenous administration of HSA-PEG/PTX nanoparticles achieved prolonged systemic circulation and enhanced tumor targeting, ultimately leading to improved therapeutic outcomes and extended survival.